The use of the Johnson & Johnson vaccine in Europe was postponed due to blood clots

The company postponed the deployment of its vaccine in the EU due to information about thrombosis among those vaccinated with Janssen.

The American company Johnson & Johnson has postponed the start of use in Europe of its Janssen coronavirus vaccine – because of information about the formation of blood clots in people who took it.

This is stated in today’s statement by J&J.

“We have decided in advance to postpone the deployment of our vaccine in Europe,” the document says.

The company, together with European health authorities, is studying data on thrombosis among vaccinated people, as well as working with experts on this issue and advocating for ” open communication of this information to medical professionals and the public.”

Earlier in the day, the U.S. Centers for Disease Control and Prevention (CDC) and the U.S. Food and Drug Administration (FDA) recommended suspending the use of the Johnson & Johnson coronavirus vaccine.

According to their data, for 6.8 million doses of the Johnson & Johnson vaccine administered in the United States, six cases of “rare and complex” cases of thrombosis were detected.

That is, blood clots were formed in 0.0001% of patients. All the victims were women aged 18-48 years, and the side effect appeared in the 6-13 days after vaccination.

Against this background, a meeting of the CDC’s Advisory Committee on Immunization Practices will be convened on April 14 to assess the potential significance of such cases. The FDA also considers information about thrombosis in vaccinated patients.

“Until this process is complete, as a precautionary measure, we recommend pausing the use of this vaccine,” said CDC Deputy Director Anna Schuchat and director of the FDA’s Center for Biologics Evaluation and Research Peter Marks.

Earlier, similar side effects were found in the AstraZeneca vaccine. This was officially confirmed by the European Medicines Agency, but the reason for this connection remains unclear.

For its part, the World Health Organization noted the high effectiveness of the J&J vaccine against new coronavirus mutations.

Merkel to take away powers from regional heads to fight COVID-19

The German Chancellor has clashed with the prime ministers of the states over restrictions on the coronavirus since the beginning of the pandemic, as some of them have not provided the measures agreed with her.

The coalition under the leadership of German Chancellor Angela Merkel decided to transfer to the government the right to impose restrictions due to the COVID-19 coronavirus throughout the country. About this on Saturday, April 10, writes Bloomberg.

It is reported that the Chancellor’s administration has developed a bill that will deprive the heads of 16 federal states of the ability to tighten or relax coronavirus restrictions. So far, the authorities of each German region can make such decisions independently. The government will be given the right to impose restrictions due to COVID-19 throughout the country.

The document, which was reviewed by the agency, says that Merkel plans to impose a curfew from 21.00 to 05.00 in those regions where the incidence rate over the past seven days will exceed 100 cases per 100 thousand people for three consecutive days. Non-food stores located in these lands will have to close, and companies will be required to test employees for coronavirus twice a week. In those regions where the incidence exceeds 200 cases per 100 thousand people, schools will also be closed.

“The biggest obstacle to this proposal is likely to be a vote in the upper house, where the governments of the states are represented, and Merkel’s ruling coalition, led by the Christian Democratic Union, does not have a majority,” the publication says.

Recall that the residents of Germany, who received vaccination against coronavirus, will soon be able to regain their rights and freedoms.

The European Commissioner said that the “Satellite V” will come to the EU too late

Commissioner for Internal Market Affairs Thierry Breton, who oversees vaccination policy in the European Commission (EC), said that even after the approval of the European regulator, the Russian vaccine “Sputnik V” will come to the EU “too late”.

“I am convinced that the European Medicines Agency (EMA) will study Sputnik V and give it a correct assessment. But a possible approval would not mean that the vaccine can be produced in sufficient quantities. It usually takes many months before the corresponding products can be established and expanded. For our goal — to vaccinate as many Europeans as possible in the summer — Sputnik V will simply come too late, “ Breton said in an interview with Spiegel.

At the same time, according to him, the European Union will have enough vaccines to achieve collective immunity in the summer.

Breton has previously said that Europe will not need Sputnik V, as the EU has already approved four other drugs, which will be enough to achieve collective immunity. Before that, he called the Russian vaccine good but said that it is necessary to establish its products in the European Union, and in this Russia may need help.

Russian President Vladimir Putin has previously noted that Moscow does not impose its vaccine on anyone, but when there are statements that it is not needed in Europe, the question arises who’s interests they support-citizens or pharmaceutical companies.

The Austrian Chancellor announced the completion of negotiations on the purchase of Sputnik V

Austrian Chancellor Sebastian Kurz announced the completion of negotiations with Russia on the purchase of the vaccine from COVID-19 “Sputnik V”.

“Purchasing for us in Austria is possible,” Kurz said.

Kurz noted that the purchase of a million doses of Sputnik V would speed up vaccination in Austria.

Earlier it was reported that Austria expects to get a quick admission of the Russian vaccine against the coronavirus “Sputnik V” from the European Medicines Agency (EMA). The country does not exclude that it will register the drug itself.

On March 4, the European Medicines Agency announced the start of the procedure for the sequential examination of the Sputnik V vaccine.

J&J vaccine and thrombosis: EU begins check

The EMA will check reports that those vaccinated against the coronavirus with the J&J drug in the United States have experienced side effects.

The European Medicines Agency (EMA) will check information about possible severe side effects of the Johnson & Johnson vaccine before the drug is actually used in the European Union. This was reported by the EMA on Friday, April 9.

As specified in the agency’s message, we are talking about the occurrence of thrombosis after vaccination. The vaccine of the American pharmaceutical company Johnson & Johnson was approved by the European Commission for use in the EU in March this year.

Reports of side effects from J&J in the US

Earlier, on April 8, it was reported that in the US state of North Carolina, the vaccination center against COVID-19 was temporarily closed after several people showed side effects after being vaccinated with the J&J vaccine. A day earlier, the same measures were followed in the state of Denver, where patients after vaccination with this drug complained of dizziness and nausea.

J&J Vaccine Benefits

Unlike most other vaccines, the J&J vaccine only needs to be given once, so more people can get access to the vaccine. In addition, the J&J vaccine does not require ultra-low temperatures to be stored and transported. Like the AstraZeneca and Sputnik V vaccines, J&J is a vector vaccine.

The U.S. Food and Drug Administration (FDA) registered the J&J vaccine in February 2021. The results of phase 3 clinical trials indicate that this drug reduces the risk of moderate to severe coronavirus by 66% after four weeks of vaccination.